The British pharmaceutical giant said it wants to redirect resources to its most promising medicines and vaccines. It also wants to simplify its organisation and work more efficiently and competitively.
According to the ABVV Chemie trade union, the restructuring will affect 482 white-collar employees and 735 managers.
The vaccine producer is one of Wallonia’s biggest employers, with sites in Wavre and Rixensart in Walloon Brabant, and Gembloux in Namur Province. The company employs 8,500 people.
GSK says it will remain Belgium’s largest pharmaceutical employer even after the reorganisation. It also assures staff that GSK Belgium will continue to play a key role within the group.
The announcement did not come entirely out of the blue. The unions have been fearing bad news for some time. The workforce has also fallen by 850 over the past few years due to natural attrition and temporary contracts not being renewed.
The unions point, among other things, to declining vaccine volumes. GSK is focusing on high-value vaccines, producing fewer doses but generating higher returns. “But lower volumes also mean less work and fewer jobs,” the socialist trade union said.
The vaccine market has also changed since the coronavirus pandemic. Whereas it was previously dominated by major players such as GSK, Sanofi, Merck and Pfizer, many smaller pharmaceutical companies are now active in the market too.
GSK has also shifted direction. The company is focusing more on cancer and immunotherapies, although vaccine production remains a key part of the group’s business.
Finally, the unions also point to U.S. import tariffs aimed at boosting domestic production.
That does not change the fact that GSK is highly profitable, says Thomas Benoussaid, a representative of the Christian trade union. Last year, it made a profit of 2.4 billion euros in Belgium. Shareholders received 5.5 billion euros in dividends.
The initial translation of this content was generated by AI. All facts, context, and language have subsequently been verified and validated by a human editorial team.
Read more